A cancer vaccine made just for you. mRNA is back and it's fighting melanoma
A new clinical trial has shown promising results for a personalized mRNA vaccine combined with immunotherapy in preventing melanoma recurrence. The study found that 68.8% of patients receiving the combination therapy remained cancer-free after five years, compared to 49.1% for those on immunotherapy alone. This approach tailors the vaccine to each patient's tumor, potentially improving outcomes for high-risk melanoma patients.
- ▪Connie Franciosi participated in a trial testing a personalized mRNA vaccine for melanoma.
- ▪The trial included 157 patients and showed a 49% reduction in the risk of cancer recurrence with the combination therapy.
- ▪Dr. Janice Mehnert highlighted the unique approach of using personalized immunotherapy to optimize patient outcomes.
Opening excerpt (first ~120 words) tap to expand
Health A cancer vaccine made just for you. mRNA is back and it's fighting melanoma June 1, 20268:00 AM ET Allison Aubrey Connie Franciosi, 80, was part of a trial that looked at using an mRNA vaccine and an immunotherapy drug to prevent the recurrence of melanoma. Lynn Winkler hide caption toggle caption Lynn Winkler Connie Franciosi, 80, noticed a suspicious spot on her skin and was diagnosed with melanoma in 2020. "It was considered a late diagnosis," she says. The skin cancer can be difficult to treat if it's not detected and treated early, and it can spread to other parts of the body. There are approximately 112,000 melanomas diagnosed in the U.S. each year and about 8,500 deaths.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at NPR Topics: News.
Discussion
0 commentsMore from NPR Topics: News
